NasdaqCM:NEOHealthcare
Has NeoGenomics (NEO) Priced In Its Turnaround Following Q2 Profitability?
NeoGenomics earnings shift puts Q2 profitability in focus
NeoGenomics (NEO) returned to profitability in the second quarter of 2026, reporting net income of US$2.24 million on sales of US$201.66 million, compared with a net loss a year earlier.
See our latest analysis for NeoGenomics.
At a share price of US$16.57, NeoGenomics has seen strong momentum build over 2026, with a 90 day share price return of 84.93% and a 1 year total shareholder return of 185.69%. This reflects shifting...